Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today

BusinesswireMay 7 20:00

Rallybio Price Target Maintained With a $8.00/Share by JMP Securities

Rallybio Price Target Maintained With a $8.00/Share by JMP Securities

Dow JonesApr 19 01:29

J.P. Morgan Securities: Reiterates the Rallybio (RLYB.US) rating and adjusted from superior to superior market rating, with a target price of $8.00.

J.P. Morgan Securities: Reiterates the Rallybio (RLYB.US) rating and adjusted from superior to superior market rating, with a target price of $8.00.

Zhitong FinanceApr 19 01:21

JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:RLYB) with a Market Outperform and maintains $8 price target.

BenzingaApr 19 01:18

Rallybio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 346.93% JMP Securities → $8 Reiterates Market Outperform → Market Outperform 04/11/2024 514.53%

BenzingaApr 19 01:17

Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment

TipRanksApr 18 07:15